Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study

Abuhasira, Ran; Haviv, Yosef S.; Leiba, Merav; Leiba, Adi; Ryvo, Larisa; Novack, Victor

doi:10.1016/j.ejim.2021.01.005

Cited by 18 publications

(20 citation statements)

References 50 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been observed that people who use cannabis frequently may develop hypotension and bradycardia with use, which could also trigger acute coronary ischemia. 15,16 Second, cannabis smoking is associated with decreased myocardial oxygen supply. Cannabis combustion generates significant carbon monoxide, and smoking cannabis markedly increases carboxyhemoglobin levels.…”

Section: Cannabiserelated Myocardial Infarctionmentioning

confidence: 99%

Drugs of Misuse: Focus on Vascular Dysfunction

Middlekauff

Cooper

Strauss

2022

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Section: Cannabiserelated Myocardial Infarctionmentioning

confidence: 99%

Drugs of Misuse: Focus on Vascular Dysfunction

Middlekauff

Cooper

Strauss

2022

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…To date, research on the effects of cannabinoid compounds on cardiovascular function is conflicting, with some studies showing cardioprotection and others showing adverse cardiovascular outcomes ( Mittleman et al, 2001 ; Mukamal et al, 2008 ; Wolff et al, 2011 ; Abuhasira et al, 2021 ). These disparate findings may reflect differences in cannabinoids and the models used, mode of administration, or effects on cannabinoid versus other receptors in the periphery and central nervous system.…”

Section: Discussionmentioning

confidence: 99%

Acute Cannabigerol Administration Lowers Blood Pressure in Mice

et al. 2022

View full text Add to dashboard Cite

Cannabigerol is a cannabinoid compound synthesized by Cannabis sativa, which in its acid form acts as the substrate for both Δ9-tetraydrocannabinol and cannabidiol formation. Given its lack of psychoactive effects, emerging research has focused on cannabigerol as a potential therapeutic for health conditions including algesia, epilepsy, anxiety, and cancer. While cannabigerol can bind to classical cannabinoid receptors, it is also an agonist at α2-adrenoreceptors (α2AR) which, when activated, inhibit presynaptic norepinephrine release. This raises the possibility that cannabigerol could activate α2AR to reduce norepinephrine release to cardiovascular end organs to lower blood pressure. Despite this possibility, there are no reports examining cannabigerol cardiovascular effects. In this study, we tested the hypothesis that acute cannabigerol administration lowers blood pressure. Blood pressure was assessed via radiotelemetry at baseline and following intraperitoneal injection of cannabigerol (3.3 and 10 mg/kg) or vehicle administered in a randomized crossover design in male C57BL/6J mice. Acute cannabigerol significantly lowered mean blood pressure (−28 ± 2 mmHg with 10 mg/kg versus −12 ± 5 mmHg vehicle, respectively; p = 0.018), with no apparent dose responsiveness (−22 ± 2 mmHg with 3.3 mg/kg). The depressor effect of cannabigerol was lower in magnitude than the α2AR agonist guanfacine and was prevented by pretreatment with the α2AR antagonist atipamezole. These findings suggest that acute cannabigerol lowers blood pressure in phenotypically normal mice likely via an α2AR mechanism, which may be an important consideration for therapeutic cannabigerol administration.

show abstract

“…Recently, Haleem et al found no association between cannabis use and hypertension incidence in the United States’ National Epidemiologic Survey on Alcohol and Related Conditions [ 28 ]. Elsewhere, after three months of cannabis-based treatment, blood pressure declined in 26 older adults with hypertension [ 29 ]. There are also conflicting results about the consequences of abrupt cessation of heavy cannabis use on blood pressure; some authors suggest it may cause clinically significant increases in blood pressure in a subset of users [ 42 ], while others did not find this result [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the general population, cannabis use tends to be associated with a lower risk of meeting the criteria for metabolic syndrome diagnosis [ 24 , 25 ], which may be mediated by a body weight-lowering effect of cannabis [ 25 ]. However, contrasting results have been observed for hypertension [ 26 , 27 , 28 , 29 ] and for dyslipidemia [ 30 ] when taken individually. These various points, and the fact that cannabis use is a modifiable factor, underline the need to explore the relationships between cannabis use and metabolic disorders in HCV-infected patients in order to (i) increase understanding about the mechanisms related to extrahepatic manifestations of HCV infection, and (ii) document the metabolic impacts of cannabis use, with a view to guiding further research that may benefit both HCV-infected and non-infected people.…”

Section: Introductionmentioning

confidence: 99%

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort)

Barré

Bourlière

Ramier

et al. 2022

JCM

View full text Add to dashboard Cite

Background and Aims. Hepatitis C virus (HCV) infection is associated with the onset of metabolic disorders which constitute risk factors for liver disease progression. Their impact may persist after the HCV infection has been cured. Cannabis use is associated with a lower risk of obesity and diabetes in both general and HCV populations. The associations between cannabis use and both dyslipidemia and hypertension have not yet been studied in persons with chronic HCV infection. Methods. Using cross-sectional data from the French ANRS CO22 Hepather cohort, we used regression models to test for an inverse relationship between cannabis use and (i) dyslipidemia, (ii) hypertension, and (iii) the total number of metabolic disorders. Results. Among the 6364 participants in the study population, both former and current cannabis use were associated with a lower risk of hypertension and fewer metabolic disorders. These results were independent of central obesity. Cannabis use was not associated with dyslipidemia. Conclusions. In people chronically infected with HCV, cannabis use was associated with a lower risk of hypertension and a lower number of metabolic disorders. Post-HCV cure studies are needed to confirm these findings using longitudinal data and to test whether they translate into reduced mortality in this population.

show abstract

Cannabis is associated with blood pressure reduction in older adults – A 24-hours ambulatory blood pressure monitoring study

Cited by 18 publications

References 50 publications

Drugs of Misuse: Focus on Vascular Dysfunction

Drugs of Misuse: Focus on Vascular Dysfunction

Acute Cannabigerol Administration Lowers Blood Pressure in Mice

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort)

Contact Info

Product

Resources

About